Bora Pharmaceuticals Co., Ltd. (TPE:6472)

Market Cap	47.18B -36.4%
Revenue (ttm)	18.54B -2.7%
Net Income	1.61B -64.6%
EPS	8.56 -73.1%
Shares Out	126.99M
PE Ratio	41.50
Forward PE	11.72
Dividend	10.00 (2.75%)
Ex-Dividend Date	Jun 20, 2025

Volume	1,318,353
Open	364.50
Previous Close	363.00
Day's Range	360.50 - 377.00
52-Week Range	330.50 - 795.00
Beta	0.45
Analysts	Buy
Price Target	741.35 (+99.56%)
Earnings Date	Aug 10, 2026

About Bora Pharmaceuticals

Bora Pharmaceuticals Co., Ltd. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibioti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6472

Financial Performance

In 2025, Bora Pharmaceuticals's revenue was 19.01 billion, an increase of 9.11% compared to the previous year's 17.43 billion. Earnings were 2.98 billion, a decrease of -22.61%.

Analyst Summary

According to 7 analysts, the average rating for 6472 stock is "Buy." The 12-month stock price target is $741.35, which is an increase of 99.56% from the latest price.

Price Target

$741.35

(99.56% upside)

Analyst Consensus: Buy